At what enterprise value was INOVIE GROUP acquired in 2020?

During the acquisition of INOVIE GROUP by ARDIAN in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of INOVIE GROUP when it was acquired by ARDIAN?

The estimated EV/EBITDA multiple for INOVIE GROUP is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was INOVIE GROUP acquired by ARDIAN?

INOVIE GROUP was acquired by ARDIAN in 2020.

What was the revenue of INOVIE GROUP at the time of the deal?

The revenue of INOVIE GROUP at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of INOVIE GROUP during the acquisition?

INOVIE GROUP's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the INOVIE GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the INOVIE GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-entre-en-negociations-exclusives-pour-accompagner-le-developpement

← DATABASE

Home Database Healthcare & PharmaINOVIE GROUP

11/2020

INOVIE GROUP acquired by ARDIAN

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 1b - 4b EUR

Context

Ardian led a consortium to acquire a minority stake (approx. 40% of financial rights) in Inovie. Due to French law (SEL), clinical biologists must retain the majority of voting rights and capital. The deal was designed to solve a "generational transition" problem, allowing ~130 older biologists to retire and cash out their shares while enabling younger biologists to buy in at normalized salary levels. The capital injection was earmarked for massive consolidation (Buy-and-Build) in the fragmented French lab market and for scaling specialized diagnostics.

INOVIE GROUP, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Inovie is the leading independent (physician-led) medical diagnostic group in France. It operates a massive network of over 650 laboratory sites across France, managing genomics, molecular biology, fertility treatment, and specialized diagnostic services. The group handles millions of patient procedures annually and serves over 1,500 medical institutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2020	RADIOLOGY PARTNERS	MEDNAX RADIOLOGY SOLUTIONS	UNITED STATES	Radiology
12/2020	ANTIN INFRASTRUCTURE	HIPPOCRATES (LAF - LA FARMACIA)	ITALY	Pharmacy
11/2020	APHEON (EX ERGON)	VIDACURA	GERMANY	Nursing Homes
11/2020	DWS GROUP	MEDIPASS	ITALY	Radiology
11/2020	MEDICA GROUP	GLOBAL DIAGNOSTICS	IRELAND	Radiology
11/2020	L CATTERTON	ALLIANCE ANIMAL HEALTH	UNITED STATES	Vet Clinics
10/2020	KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS	ELSAN	FRANCE	Clinics / Hospitals
10/2020	THE VISTRIA GROUP / CENTERBRIDGE PARTNERS	HELP AT HOME	UNITED STATES	Nursing Homes
10/2020	INFRATIL	QSCAN GROUP	AUSTRALIA	Radiology
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of INOVIE GROUP by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian